Business Model Breakdown
How Terns Pharmaceuticals Inc Makes Money
TERN
Market Cap
$6.1B
Profit Margin
0.0%
Employees
59
The Short Version
Terns Pharmaceuticals Inc. was a clinical-stage biopharmaceutical company focused on developing novel treatments for oncology and non-alcoholic steatohepatitis (NASH). It did not generate revenue from product sales, instead relying on financing and potential partnerships to fund its research and development pipeline. Its primary value resided in its intellectual property and the potential future commercialization of its drug candidates, such as TERN-701 for chronic myeloid leukemia (CML). This business model was based on advancing drugs through clinical trials to either commercialize them directly or, as now, be acquired by a larger pharmaceutical company.
Where the Revenue Comes From
No current product revenue (0%)
Potential future licensing fees or milestones (now part of Merck's structure)
Who buys: Historically, future customers would be patients via healthcare providers; currently, its primary 'customer' was Merck for its pipeline assets.
Why It Works (Competitive Advantages)
- ✔TERN-701, a highly selective BTK inhibitor for B-cell malignancies (now a Merck asset)
- ✔Pipeline focused on oncology and NASH (now integrated into Merck's R&D)
Economic Moat: Narrow (Intangible Assets/IP (pharmaceutical pipeline and drug candidates))
What Our Analysis Says
DVR Score as of April 5, 2026
Score Change Explanation: The drastic score reduction from 70/100 to 10/100 is due to the fundamental change in Terns Pharmaceuticals' investment profile. On March 25, 2026, Merck agreed to acquire TERN for $53/share cash. This acquisition eliminates TERN's independent 10x growth potential, which was the core thesis of the previous analysis. For existing shareholders, the upside is now capped at the acquisition price, transforming the investment from a high-growth opportunity into an M&A arbitrage play with minimal remaining upside. The original criteria of future market leadership, competitive advantages, and strategic positioning for 10x growth are no longer applicable to TERN as a standalone public entity. Terns Pharmaceuticals no longer represents a viable high-risk, high-reward 10x growth opportunity due to its impending acquisition by Merck for $53/share. While the acquisition validates its pipeline, particularly TERN-701, it caps all significant upside for current shareholders. The company's financials, strategic vision, and future catalysts are now largely irrelevant as an independent investment. Lingering risks include regulatory clearance, shareholder investigations, and potential deal termination. This stock is now a short-term arbitrage play rather than a long-term growth investment.